Back to News
Market Impact: 0.25
Hikma Pharmaceuticals Raises Profit Floor as Branded Growth Offsets Injectables Slowdown
Source: marketbeat.com
Corporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Hikma Pharmaceuticals maintained its 2026 revenue growth outlook and narrowed its operating profit guidance, with no revised figures provided. Stronger performance in its Branded business helped offset a slower-than-expected rollout of an injectable product.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
HIK0.10
More News
- Hikma Pharmaceuticals narrows profit guidance, upgrades branded unit
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request